Publications by authors named "D Dosanjh"
Article Synopsis
- - The role of neutrophils, a common type of immune cell, in interstitial lung diseases (ILDs) is under investigation due to their potential involvement in lung tissue damage and repair.
- - Studies show increased neutrophil levels in ILD patients may indicate disease severity, and their proteins and structures can contribute to fibrosis in lung tissue.
- - The review highlights a need for more research on neutrophils as both biomarkers and therapeutic targets, as understanding their actions could lead to better treatment options for ILD.
Nosocomial infection has significant consequences in health care, both at the individual level due to increased morbidity and mortality, and at the organizational level due to increased costs. Hospital-acquired pneumonia (HAP) is the most common nosocomial infection, and is associated with high excess mortality, frequent use of broad-spectrum antimicrobials and increased length of stay. This review explores the preventative strategies that have been examined in non-ventilator HAP (NV-HAP).
View Article and Find Full Text PDFNon-ventilated hospital-acquired pneumonia (NV-HAP) is associated with a significant healthcare burden, arising from high incidence and associated morbidity and mortality. However, accurate identification of cases remains challenging. At present, there is no gold-standard test for the diagnosis of NV-HAP, requiring instead the blending of non-specific signs and investigations.
View Article and Find Full Text PDFBackground: Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting.
Methods: 26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022.
Background: Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally occurring protein that stimulates host immune responses against most viruses, including severe acute respiratory syndrome coronavirus 2. SNG001 is a recombinant IFN-β1a formulation delivered to the lungs nebuliser.
View Article and Find Full Text PDF